{
	"kja6iwl6Text": "Jacobsen PL et al. 2015a<span class=\"_ _3\"></span><span class=\"fs1 v1\">1</span>",
	"kja6iwl7Text": "Safety and tolerability of Brintellix® (15 mg and 20 mg) in patients with MDD: <br>results of an open-label, flexible dose, 52-week extension study.<div style=\"line-height: 1; margin-top:5px;\">Study objective: <span class=\"ff3\">Evaluate the safety and tolerability of Brintellix® in the long-term</span></div><div class=\"ff3\">treatment of patients with MDD, as well as its effectiveness using measures of</div><div class=\"ff3\">depression, anxiety, and overall functioning.</div>",
	"kja6iwl8Text": "Primary st<span class=\"_ _0\"></span>udy objective: <span class=\"ff3\">to a<span class=\"_ _2\"></span>ssess the lon<span class=\"_ _2\"></span>g-term sa<span class=\"_ _2\"></span>fety and <br>tole<span class=\"_ _2\"></span>rabi<span class=\"_ _2\"></span>lity of hig<span class=\"_ _2\"></span>her do<span class=\"_ _2\"></span>ses of Bri<span class=\"_ _2\"></span>nte<span class=\"_ _2\"></span>llix<span class=\"_ _2\"></span>® (<span class=\"_ _c\"></span>1<span class=\"_ _c\"></span>5 mg and 2<span class=\"_ _2\"></span>0 mg<span class=\"_ _c\"></span>)<span class=\"_ _0\"></span> <br>in pat<span class=\"_ _2\"></span>ients with MD<span class=\"_ _2\"></span>D<span class=\"_ _2\"></span>. T<span class=\"_ _c\"></span>olera<span class=\"_ _2\"></span>bil<span class=\"_ _c\"></span>it<span class=\"_ _0\"></span>y assessments wer<span class=\"_ _2\"></span>e based <br>on a ≥<span class=\"_ _c\"></span>5% inc<span class=\"_ _2\"></span>iden<span class=\"_ _2\"></span>ce of TEAEs duri<span class=\"_ _2\"></span>ng the study pe<span class=\"_ _2\"></span>riod (<span class=\"_ _3\"></span>up <br>to 30 day<span class=\"_ _2\"></span>s af<span class=\"_ _0\"></span>ter th<span class=\"_ _2\"></span>e fina<span class=\"_ _2\"></span>l dose<span class=\"_ _3\"></span>). All TEAEs were e<span class=\"_ _2\"></span>val<span class=\"_ _2\"></span>uat<span class=\"_ _2\"></span>ed for <br>sev<span class=\"_ _c\"></span>erit<span class=\"_ _0\"></span>y (<span class=\"_ _c\"></span>mild, m<span class=\"_ _2\"></span>oderat<span class=\"_ _2\"></span>e, o<span class=\"_ _2\"></span>r sev<span class=\"_ _2\"></span>ere<span class=\"_ _3\"></span>) and causal r<span class=\"_ _2\"></span>elati<span class=\"_ _2\"></span>onsh<span class=\"_ _2\"></span>ip <br>with th<span class=\"_ _2\"></span>e study drug (<span class=\"_ _2\"></span>pro<span class=\"_ _2\"></span>babl<span class=\"_ _2\"></span>e, p<span class=\"_ _2\"></span>ossibl<span class=\"_ _2\"></span>e, o<span class=\"_ _2\"></span>r not r<span class=\"_ _2\"></span>elat<span class=\"_ _2\"></span>ed)<span class=\"_ _c\"></span>.</span>",
	"kja6iwl9Text": "Secondary st<span class=\"_ _0\"></span>udy objectives: <span class=\"ff3\">to a<span class=\"_ _2\"></span>ssess the effec<span class=\"_ _0\"></span>t of <br>Brin<span class=\"_ _2\"></span>tel<span class=\"_ _2\"></span>lix® on m<span class=\"_ _2\"></span>easu<span class=\"_ _2\"></span>res o<span class=\"_ _2\"></span>f depr<span class=\"_ _2\"></span>ession<span class=\"_ _c\"></span>, anxiety, a<span class=\"_ _2\"></span>nd ov<span class=\"_ _c\"></span>erall <br><span class=\"ls37 ws7d\">func<span class=\"_ _0\"></span>t<span class=\"_ _0\"></span>ioning, and<span class=\"_ _0\"></span> to evaluate<span class=\"_ _0\"></span> the<span class=\"_ _0\"></span> maintenance<span class=\"_ _0\"></span> of the<span class=\"_ _0\"></span> <br></span>therap<span class=\"_ _2\"></span>eutic effect of Brinte<span class=\"_ _2\"></span>lli<span class=\"_ _2\"></span>x® ov<span class=\"_ _2\"></span>er a peri<span class=\"_ _2\"></span>od of up t<span class=\"_ _2\"></span>o 5<span class=\"_ _2\"></span>2 <br>weeks. Se<span class=\"_ _2\"></span>cond<span class=\"_ _2\"></span>ary endpoi<span class=\"_ _2\"></span>nts were c<span class=\"_ _2\"></span>hang<span class=\"_ _2\"></span>ed from O<span class=\"_ _2\"></span>LB in <br>MADRS t<span class=\"_ _2\"></span>otal sc<span class=\"_ _2\"></span>ore<span class=\"_ _c\"></span>, HAM<span class=\"_ _0\"></span>-A total s<span class=\"_ _2\"></span>core<span class=\"_ _c\"></span>, SDS to<span class=\"_ _2\"></span>tal scor<span class=\"_ _2\"></span>e, a<span class=\"_ _2\"></span>nd <br><span class=\"ls38 ws7e\">CGI-S score.</span></span>",
	"kja6iwlaText": "Completion<span class=\"_ _0\"></span> <br><span class=\"ls1a wsb\">visit from <br><span class=\"ls39 ws61\">lead-<span class=\"_ _0\"></span>in stu<span class=\"_ _0\"></span>dy <br><span class=\"ls3a ws2\">s<span class=\"_ _0\"></span>er<span class=\"_ _0\"></span>ved a<span class=\"_ _0\"></span>s<span class=\"_ _0\"></span> <br><span class=\"ls2b ws7f\">open-label <br></span></span></span>baseline visit<span class=\"_ _0\"></span> <br><span class=\"ls3b ws80\">(<span class=\"_ _0\"></span>A<span class=\"_ _0\"></span>P<span class=\"_ _1\"></span>T<span class=\"_ _0\"></span>S<span class=\"_ _1\"></span> n<span class=\"_ _0\"></span>=107<span class=\"_ _0\"></span>3)</span></span>",
	"kja6iwlbText": "No fur<span class=\"_ _0\"></span>ther <br><span class=\"ls1 ws9\">drug<span class=\"_ _0\"></span> <br></span><span class=\"ws7b\">dispensed</span>",
	"kja6iwlcText": "Key inclusion criteria ",
	"kja6iwldText": "P<span class=\"_ _c\"></span>atients completing<span class=\"_ _0\"></span> <br>one of three short-term <br>studies: NCT01153009, <br>NCT01163266, or <br><span class=\"ws81\">NCT01179516 </span>",
	"kja6iwleText": "Men and women aged 18-75 ",
	"kja6iwlfText": "P<span class=\"_ _2\"></span>rimary diagnosis of recurrent <br>MDD<span class=\"_ _2\"></span>, accor<span class=\"_ _2\"></span>ding to DSM-IV <br><span class=\"ws81\">criteria<span class=\"_\"> </span> </span>",
	"kja6iwlgText": "Continuation of treatment ",
	"kja6iwlhText": "Clinically indicated",
	"kja6iwliText": "All patients initiated on <br>Brintellix® 10 mg/day for the <br>first week.<span class=\"_ _2\"></span> Af<span class=\"_ _2\"></span>ter the first week, <br>dose was titr<span class=\"_ _2\"></span>ated to either <br>15 or 20 mg/day Brintellix® <br>on the basis of response and <br><span class=\"ws7c\">tolerability</span>",
	"kja6iwljText": "<div style=\"text-align: center; line-height:1.3;\">Final visit at</div><div style=\"text-align: center;\">week 52 and<br></div><div style=\"text-align: center;\"><span style=\"text-align: start;\">safety call</span><br></div>",
	"kja6iwlmText": "Back",
	"Brintellix_7380ee76c5": "<span class=\"ff2 fc0 fs13\">References</span>",
	"Brintellix_73ae1cb5b2": "<div class=\"ff3 fc1\" style=\"font-size:15px;\"><span class=\"ff2\">1.</span> Jacobsen PL et al. Int Clin Psychopharmacol 2015;30:225-264.</div>"
}
